Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Core Insights - ALLO-329 is an investigational allogeneic CAR T cell therapy targeting both CD19+ B cells and CD70+ activated T cells, showing promise in treating autoimmune diseases without lymphodepletion [1][2][4] - The company plans to submit an Investigational New Drug (IND) application for ALLO-329 in Q1 2025, with proof-of-concept expected by the end of 2025 [1][5] Group 1: ALLO-329 Mechanism and Technology - ALLO-329 utilizes proprietary Dagger® technology to overcome rejection and expand alloreactive T cells, potentially enhancing therapeutic benefits [1][3][6] - The therapy demonstrates high CAR expression and cytotoxic activity against both targeted cell types, indicating robust efficacy [4][5] - ALLO-329 effectively depletes B cells and reduces IgG and IgM production in preclinical models, suggesting a significant impact on autoimmune disease pathology [4][5] Group 2: Competitive Landscape and Development Plans - The CAR T therapy market for autoimmune diseases is competitive, with ALLO-329's dual targeting approach setting it apart by addressing a broader spectrum of immune dysfunction [4][6] - The company aims to provide "off-the-shelf" CAR T products, which could meet the substantial needs of a wide patient population [4][7]